Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Medicine  4, 460 - 463 (1998)
doi:10.1038/nm0498-460

Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin

V. Jevtovi-Todorovi1, S. M. Todorov1, S. Mennerick2, S. Powell2, K. Dikranian2, N. Benshoff2, C. F. Zorumski2 & J. W. Olney2

  1Department of Anesthesiology, Washington University School of Medicine, Campus Box 8054, 660 S. Euclid Avenue, St.Louis, Missouri, 63110, USA.

  2Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 4940 Childrens Place, St.Louis, Missouri, 63110, USA.

 Correspondence should be addressed to V. Jevtovi-Todorovi

Extensive research has failed to clarify the mechanism of action of nitrous oxide (N2O, laughing gas), a widely used inhalational anesthetic and drug of abuse. Other general anesthetics are thought to act by one of two mechanisms—blockade of NMDA glutamate receptors or enhancement of CABAergic inhibition1. Here we show that N2O, at anesthetically-relevant concentrations, inhibits both ionic currents and excitotoxic neurodegeneration mediated through NMDA receptors and, like other NMDA antagonists, produces neurotoxic side effects which can be prevented by drugs that enhance CABAergic inhibition. The favorable safety record of N2O may be explained by the low concentrations typically used and by the fact that it is usually used in combination with CABAergic anesthetics that counteract its neurotoxic potential.

REFERENCES
  1. Franks, N.P. & Lieb, W.R. Molecular and cellular mechanisms of general anaesthesia. Nature 367, 607−614 (1994). | Article | PubMed  | ISI | ChemPort |
  2. Lodge, D. & Anis, N.A. Effects of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat. Eur. J. Pharmacol. 77, 203−204 (1982). | Article | PubMed  | ISI | ChemPort |
  3. Lodge, D. et al. Excitatory amino acids and Phencyclidine-like drugs. In: Excitatory Amino Acid Transmission . Hicks TP, Lodge D and McLennan H (Eds). (New York: Alan R. LissInc), pp 83-90 (1987).
  4. Rothman, S.M. The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J.Neumsci. 4, 1483−1489 (1991).
  5. Choi, D.W. Glutamate neurotoxicity and disease of the nervous system. Neuron 1, 623−634 (1988). | PubMed  | ISI | ChemPort |
  6. Olney, J.W. Excitatory amino acids and neuropsychiatric disorders. Biol. Psychiatry 26, 505−525 (1989). | Article | PubMed  | ISI | ChemPort |
  7. Olney, J.W., Labruyere, J. & Price, M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244, 1360−1362 (1989). | PubMed  | ISI | ChemPort |
  8. Fix, A.S. et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (Dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neural. 123, 204−215 (1993). | Article | ChemPort |
  9. Farber, N.B. et al. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia? Biol. Psychiatry 38 788−796 (1995). | Article | PubMed  | ISI | ChemPort |
  10. Olney, J.W. et al. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 254, 1515−1518 (1991). | PubMed  | ISI | ChemPort |
  11. Ishimaru, M., Fukamauchi, F. & Olney, J.W. Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex. Neurosci. Lett. 193, 1−4 (1995). | Article | PubMed  | ISI | ChemPort |
  12. Jevtovic-Todorovic, V., Kirby, C.O. & Olney, J.W. Isoflurane and propofol block neurotoxicity caused by MK-801 in the rat posterior cingulate/retrosplenial cortex. J. Cereb. Blood Flow and Met. 17, 168−174 (1997). | Article | ChemPort |
  13. Stevens, R.K. & Scheller, M. Anesthesia as a Speciality: Past, Present and Future. In Clinical Anesthesia, Barash PG et al., Ed. (Philadelphia, JB Lippincott), pp. 6 (1992).
  14. Little, H.J. & Thomas, D.L. The effects of anaesthetics and high pressure on the responses of the rat superior cervical ganglion in vitro. J. Physiol. 374, 387−399 (1986). | PubMed  | ISI | ChemPort |
  15. Koblin, D.D., Deady, J.E., Nelson, N.T., Eger, E.I. & Bainton, C.R. Mice tolerant to nitrous oxide are not tolerant to barbiturates. Anesth. Analg. 60, 138−141 (1981). | PubMed  | ISI | ChemPort |
  16. Olney, J.W. & Price, M.T. Excitotoxic amino acids as neuroendocrine research tools. In: Neuroendocrine Peptide Methodology, P. Michael Conn, (Ed.) (San Diego, California: Academic Press), pp.891-905 (1989).
  17. Wong, E.H. et al. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. U.S.A. 83, 7104−7108 (1986). | PubMed  | ChemPort |
  18. Olney, J.W., Price, M.T., Shahid Salles, K., Labruyere, J. & Frierdich, G.MK-801 powerfully protects against N-methyl aspartate neurotoxicity.Eur. J. Pharmacol. 141, 357−361 (1987). | Article | PubMed  | ISI | ChemPort |
  19. Mennerick, S., Que, J., Benz, A., A. & Zorumski, C.F. Passive and synaptic properties of hippocampal neurons grown in microcultures and in mass cultures. J. Neurophysiology 73, 320−332 (1995). | ISI | ChemPort |
  20. Stevens, W.C. & Kingston, H.C.G., Inhalation Anesthesia In Clinical Anesthesia Barash P.G. et al., (Ed.) (Philadelphia, JB Lippincott), 439−465 (1992).
  21. Fragen, R.J. & Avram, M.J., Nonopioid Intravenous AnestheTics. Clinical Anesthesia, Barash, P.G. et al. (Eds.) (Philadelphia: JB Lippincott), 385−412 (1992).
  22. Hornbein, T.F. et al. The minimum alveolar concentration of nitrous oxide in man. Anest. Analg. 61, 553−556 (1982). | ISI | ChemPort |
  23. Gonsowski, C.T. & Eger II, E.I. Nitrous oxide minimum alveolar anesthetic concentration in rats is greater than previously reported. Anesth. Analg. 79, 710−712 (1994).
  24. Mahmoudi, N.W., Cole, D.J. & Shapiro, H.M. Insufficient anesthetic potency of nitrous oxide in the rat. Anesthesiology 70, 345 (1989). | PubMed  | ChemPort |
  25. Dohm, C.S. et al. Reinforcing effects of extended inhalation of nitrous oxide in humans. Drug Alcohol Depend. 31, 265−280 (1993). | Article | PubMed  |
 Top
 Top
Abstract
Previous | Next
Table of contents
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

naturejobs

References
Export citation
Export references
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©1998 Nature Publishing Group | Privacy policy